Perth-based precision medicine company PYC Therapeutics (ASX:PYC) announced a milestone in its clinical trial program for polycystic kidney disease.
The company confirmed that it has received approval from its Safety Review Committee to escalate dosing in its PYC-003 drug candidate trial.
The approval follows a comprehensive review of the 4-week safety data from the first two cohorts—B1 and B2—in Part B of the single ascending dose study, which is currently being conducted in patients suffering from PKD.
Following the favourable safety results, the trial will now proceed to the third cohort, B3.
PYC-003 is being developed to address the underlying genetic causes of PKD, a disease that currently has limited treatment options available for patients.
By escalating the dose without significant safety concerns in the initial cohorts, the company aims to determine the optimal dosage for efficacy in future studies.
The clinical trial continues to advance, bringing hope to the PKD community for a potential therapeutic breakthrough.
At the time of reporting, PYC Therapeutics' share price was $1.50.